Fintel reports that on August 22, 2023, JP Morgan maintained coverage of Y-Mabs Therapeutics (NASDAQ:YMAB) with a Underweight recommendation.
Analyst Price Forecast Suggests 108.16% Upside
As of August 2, 2023, the average one-year price target for Y-Mabs Therapeutics is 13.11. The forecasts range from a low of 7.07 to a high of $23.10. The average price target represents an increase of 108.16% from its latest reported closing price of 6.30.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Y-Mabs Therapeutics is 74MM, a decrease of 12.66%. The projected annual non-GAAP EPS is -1.79.
What is the Fund Sentiment?
There are 233 funds or institutions reporting positions in Y-Mabs Therapeutics. This is an increase of 3 owner(s) or 1.30% in the last quarter. Average portfolio weight of all funds dedicated to YMAB is 0.03%, an increase of 9.17%. Total shares owned by institutions increased in the last three months by 1.50% to 21,059K shares. 
The put/call ratio of YMAB is 0.02, indicating a bullish outlook.
What are Other Shareholders Doing?
Sofinnova Investments holds 2,194K shares representing 5.03% ownership of the company. No change in the last quarter.
Polar Capital Holdings holds 2,103K shares representing 4.82% ownership of the company. In it's prior filing, the firm reported owning 1,992K shares, representing an increase of 5.29%. The firm increased its portfolio allocation in YMAB by 35.42% over the last quarter.
D. E. Shaw holds 1,275K shares representing 2.92% ownership of the company. In it's prior filing, the firm reported owning 791K shares, representing an increase of 37.98%. The firm increased its portfolio allocation in YMAB by 42.12% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 1,159K shares representing 2.66% ownership of the company. No change in the last quarter.
IWM - iShares Russell 2000 ETF holds 833K shares representing 1.91% ownership of the company. In it's prior filing, the firm reported owning 891K shares, representing a decrease of 6.96%. The firm increased its portfolio allocation in YMAB by 0.28% over the last quarter.
Y-Mabs Therapeutics Background Information
(This description is provided by the company.)
Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The Company has a broad and advanced product pipeline, including one FDA approved product, DANYELZA® (naxitamab-gqgk), which targets tumors that express GD2, and one pivotal-stage product candidate, omburtamab, which targets tumors that express B7-H3.
Additional reading:
- Y-mAbs Reports Second Quarter 2023 Financial Results and Recent Corporate Developments
- Y-mAbs Announces Presentation of Naxitamab Data at ASCO
- Y-mAbs Announces Presentation of GD2-SADA Study at ASCO
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
